Terms: = Ovarian cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439
54 results:
1. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA; Tuit S; Wouters AK; van de Meent M; Siekman SL; Meeuwsen MH; Wachsmann TLA; Remst DFG; Hagedoorn RS; van der Steen DM; de Ru AH; Verdegaal EME; van Veelen PA; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2023; 14():1121973. PubMed ID: 37026005
[TBL] [Abstract] [Full Text] [Related]
2. Autologous T cell therapy for MAGE-A4
Hong DS; Van Tine BA; Biswas S; McAlpine C; Johnson ML; Olszanski AJ; Clarke JM; Araujo D; Blumenschein GR; Kebriaei P; Lin Q; Tipping AJ; Sanderson JP; Wang R; Trivedi T; Annareddy T; Bai J; Rafail S; Sun A; Fernandes L; Navenot JM; Bushman FD; Everett JK; Karadeniz D; Broad R; Isabelle M; Naidoo R; Bath N; Betts G; Wolchinsky Z; Batrakou DG; Van Winkle E; Elefant E; Ghobadi A; Cashen A; Grand'Maison A; McCarthy P; Fracasso PM; Norry E; Williams D; Druta M; Liebner DA; Odunsi K; Butler MO
Nat Med; 2023 Jan; 29(1):104-114. PubMed ID: 36624315
[TBL] [Abstract] [Full Text] [Related]
3. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in ovarian cancer.
Liu H; Lin J; Zhou W; Moses R; Dai Z; Kossenkov AV; Drapkin R; Bitler BG; Karakashev S; Zhang R
Cancer Immunol Res; 2022 Aug; 10(8):1028-1038. PubMed ID: 35726891
[TBL] [Abstract] [Full Text] [Related]
4. Substantial variability in ovarian conservation at hysterectomy for endometrial hyperplasia.
Matsuo K; Violette CJ; Mandelbaum RS; Harris CA; Tavakoli A; Klar M; Shoupe D; Roman LD
Am J Obstet Gynecol; 2022 Aug; 227(2):255.e1-255.e18. PubMed ID: 35487326
[TBL] [Abstract] [Full Text] [Related]
5. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.
Matsuzaki J; Lele S; Odunsi K; Tsuji T
Oncoimmunology; 2022; 11(1):2020983. PubMed ID: 35003898
[TBL] [Abstract] [Full Text] [Related]
6. Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced ovarian cancer.
Nishida S; Morimoto S; Oji Y; Morita S; Shirakata T; Enomoto T; Tsuboi A; Ueda Y; Yoshino K; Shouq A; Kanegae M; Ohno S; Fujiki F; Nakajima H; Nakae Y; Nakata J; Hosen N; Kumanogoh A; Oka Y; Kimura T; Sugiyama H
J Immunother; 2022 Jan; 45(1):56-66. PubMed ID: 34874330
[TBL] [Abstract] [Full Text] [Related]
7. Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2].
Takeuchi S; Kagabu M; Shoji T; Nitta Y; Sugiyama T; Sato J; Nakamura Y
Oncoimmunology; 2020 Nov; 9(1):1838189. PubMed ID: 33235818
[TBL] [Abstract] [Full Text] [Related]
8. hla-a and HLA-DRB1 may play a unique role in ovarian teratoma-associated anti-N-methyl-D-aspartate receptor encephalitis.
Zhao X; Li J; Zhu Q; Liang G; Xia W; He X; Zhu C; Qi H; Deng B; Chen X; Zhang J
Reprod Biol Endocrinol; 2020 Nov; 18(1):107. PubMed ID: 33160385
[TBL] [Abstract] [Full Text] [Related]
9. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.
Dao T; Klatt MG; Korontsvit T; Mun SS; Guzman S; Mattar M; Zivanovic O; Kyi CK; Socci ND; O'Cearbhaill RE; Scheinberg DA
Cancer Immunol Immunother; 2021 May; 70(5):1189-1202. PubMed ID: 33123756
[TBL] [Abstract] [Full Text] [Related]
10. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers.
Bradley SD; Talukder AH; Lai I; Davis R; Alvarez H; Tiriac H; Zhang M; Chiu Y; Melendez B; Jackson KR; Katailiha A; Sonnemann HM; Li F; Kang Y; Qiao N; Pan BF; Lorenzi PL; Hurd M; Mittendorf EA; Peterson CB; Javle M; Bristow C; Kim M; Tuveson DA; Hawke D; Kopetz S; Wolff RA; Hwu P; Maitra A; Roszik J; Yee C; Lizée G
Nat Commun; 2020 Oct; 11(1):5332. PubMed ID: 33087697
[TBL] [Abstract] [Full Text] [Related]
11. cancer testis antigen Cyclin A1 harbors several hla-a*02:01-restricted T cell epitopes, which are presented and recognized in vivo.
Teck AT; Urban S; Quass P; Nelde A; Schuster H; Letsch A; Busse A; Walz JS; Keilholz U; Ochsenreither S
Cancer Immunol Immunother; 2020 Jul; 69(7):1217-1227. PubMed ID: 32157447
[TBL] [Abstract] [Full Text] [Related]
12. The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.
Xu H; Duan N; Wang Y; Sun N; Ge S; Li H; Jing X; Liang K; Zhang X; Liu L; Xue C; Zhang C
Pathology; 2020 Feb; 52(2):206-212. PubMed ID: 31883669
[TBL] [Abstract] [Full Text] [Related]
13. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.
Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z
Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525
[TBL] [Abstract] [Full Text] [Related]
14. Recurrence rate and associated factors of borderline ovarian tumors in the south of Vietnam.
Vo TM; Duong KA; Tran LT; Bui TC
J Obstet Gynaecol Res; 2019 Oct; 45(10):2055-2061. PubMed ID: 31368150
[TBL] [Abstract] [Full Text] [Related]
15. Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal cancer.
Lo W; Parkhurst M; Robbins PF; Tran E; Lu YC; Jia L; Gartner JJ; Pasetto A; Deniger D; Malekzadeh P; Shelton TE; Prickett T; Ray S; Kivitz S; Paria BC; Kriley I; Schrump DS; Rosenberg SA
Cancer Immunol Res; 2019 Apr; 7(4):534-543. PubMed ID: 30709841
[TBL] [Abstract] [Full Text] [Related]
16. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract] [Full Text] [Related]
17. A modified hla-a*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.
Sun W; Shi J; Wu J; Zhang J; Chen H; Li Y; Liu S; Wu Y; Tian Z; Cao X; Li N
Cell Mol Immunol; 2018 Aug; 15(8):768-781. PubMed ID: 29375131
[TBL] [Abstract] [Full Text] [Related]
18. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
Rafiq S; Purdon TJ; Daniyan AF; Koneru M; Dao T; Liu C; Scheinberg DA; Brentjens RJ
Leukemia; 2017 Aug; 31(8):1788-1797. PubMed ID: 27924074
[TBL] [Abstract] [Full Text] [Related]
19. Identification of a naturally processed hla-a*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4.
Lopez M; Ghidouche A; Rochas C; Godelaine D; Carrasco J; Colau D; Hames G; Montero-Julian FA; Coulie PG; Olive D
Cancer Immunol Immunother; 2016 Oct; 65(10):1177-88. PubMed ID: 27514672
[TBL] [Abstract] [Full Text] [Related]
20. Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for ovarian cancer.
Patterson AM; Kaabinejadian S; McMurtrey CP; Bardet W; Jackson KW; Zuna RE; Husain S; Adams GP; MacDonald G; Dillon RL; Ames H; Buchli R; Hawkins OE; Weidanz JA; Hildebrand WH
Mol Cancer Ther; 2016 Feb; 15(2):313-22. PubMed ID: 26719579
[TBL] [Abstract] [Full Text] [Related]
[Next]
